肝移植患者的单剂量达克珠单抗诱导治疗。
Single-dose daclizumab induction therapy in patients with liver transplantation.
作者信息
Yan Lu-Nan, Wang Wei, Li Bo, Lu Shi-Chun, Wen Tian-Fu, Lin Qi-Yuan, Zeng Yong, Cheng Nan-Sheng, Zhao Ji-Chun, Dai Yue-Meng
机构信息
Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.
出版信息
World J Gastroenterol. 2003 Aug;9(8):1881-3. doi: 10.3748/wjg.v9.i8.1881.
AIM
To investigate the efficacy and safety of a single-dose daclizumab induction therapy in orthotopic liver transplantation (OLTx).
METHODS
A retrospective study was made for 54 cases of OLTx in recent three years. The daclizumab group consisted of 23 cases of OLTx who received single-dose of 2 mg/kg intravenously after postoperative 24 hours. The control group consisted of the remaining 31 patients. Additional immunosuppressors included steroids, mycomphenolate mofetil, facrolimus or microemulsion cyclosporine used in all patients. Meta-statistical analysis was made for general data, incidence of acute rejection and infection, postoperative clinical course, complications and prognosis between two groups.
RESULTS
Pretransplant demographies were not significantly different between two groups. In the induction group there were significantly less acute rejection episodes (5 of 23, 21.74 %) than those in the control group (12 of 31, 38.71 %), which were proved by pathologic diagnosis (P<0.05). The incidence of infection at the early stage was not significantly different between two groups.
CONCLUSION
Induction therapy with single-dose of daclizumab is safe and effective and appears to be able to reduce the incidence of acute rejection.
目的
探讨单剂量达利珠单抗诱导治疗在原位肝移植（OLTx）中的疗效和安全性。
方法
对近三年54例原位肝移植患者进行回顾性研究。达利珠单抗组由23例原位肝移植患者组成，术后24小时静脉注射单剂量2mg/kg。对照组由其余31例患者组成。所有患者均使用其他免疫抑制剂，包括类固醇、霉酚酸酯、他克莫司或微乳环孢素。对两组患者的一般资料、急性排斥反应和感染发生率、术后临床病程、并发症及预后进行Meta统计分析。
结果
两组移植前人口统计学特征无显著差异。诱导组急性排斥反应发生率（23例中的5例，21.74%）明显低于对照组（31例中的12例，38.71%），经病理诊断证实（P<0.05）。两组早期感染发生率无显著差异。
结论
单剂量达利珠单抗诱导治疗安全有效，似乎能够降低急性排斥反应的发生率。
Zotero 插件